# A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

> **NCT03645434** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 73 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** AZD8871
- **DRUG:** Anoro® Ellipta®

## Key facts

- **NCT ID:** NCT03645434
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-10
- **Primary completion:** 2019-08-07
- **Final completion:** 2019-08-07
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03645434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03645434, "A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03645434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*